http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102964442-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8f272629b5b48b27bbcb317ab03b17e4 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-48 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 |
| filingDate | 2012-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83be9ab9e8272252518e4e6af10dcc6f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_513ccb81b1f34489075d02aa462e5f05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f7429c23d3c8cfec83fff0d67e82fc94 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f81cbbea2f775e1f293da246ee825a09 |
| publicationDate | 2015-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102964442-B |
| titleOfInvention | Method for preparing polyethylene glycol (PEG) and nerve growth factor (NGF) conjugate |
| abstract | The invention relates to a method for preparing a polyethylene glycol (PEG) and nerve growth factor (NGF) conjugate. The method specifically comprises the following steps of: conjugating: dissolving an NGF and PEG into buffer liquid with the pH of 4-10, and stirring for 24 hours at room temperature, wherein the mass ratio of the NGF to the PEG is 1: 10; carrying out purification and recovery, thereby obtaining the PEG and NGF conjugate; and concentrating the recovered protein. The invention also discloses the PEG and NGF conjugate prepared according to the method, and compositions containing the PEG and NGF conjugate. The invention further discloses application of the PEG and NGF conjugate in medicine preparation. The method is simple and practicable; and after the NGF and the PEG are conjugated, the activity of the NGF is still kept, and the half life of the NGF in vivo can be prolonged, so that the administration frequency is reduced, and the pain of patients is reduced. |
| priorityDate | 2012-11-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 62.